Drugs / DWJ1319
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02490111 | May 2015 → Jan 2018 | gastric cancer | Daewoong Pharmaceutical Co. LTD. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWJ1319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02490111 ↗ |
| Route | Oral | “DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months” NCT02490111 ↗ |